Meeting
2021 ASCO Quality Care Symposium
Trends in use of one, two, and three-line NCCN category 1 regimens among Medicare fee-for-service (FFS) patients receiving treatment for metastatic pancreatic cancer.
Authors
Gabriela Dieguez
Milliman, Inc., New York, NY
Gabriela Dieguez, Samantha Tomicki, David DeStephano, Paul Cockrum
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Patient Experience; Quality, Safety, and Implementation Science; Technology and Innovation in Quality of Care
Track
Technology and Innovation in Quality of Care,Patient Experience,Quality, Safety, and Implementation Science,Cost, Value, and Policy,Health Care Access, Equity, and Disparities
Sub Track
Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 28; abstr 297)
DOI
10.1200/JCO.2020.39.28_suppl.297
Abstract #
297
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2022 ASCO Annual Meeting
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186—Trials in progress.
First Author: Efrat Dotan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Resource utilization and total cost of care among Medicare advantage patients with metastatic pancreatic cancer receiving NCCN category 1 preferred regimens.
First Author: Gabriela Dieguez
Poster
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
First Author: Brett A. Schroeder